Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) was downgraded by investment analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a note issued to investors on Monday.

A number of other research firms also recently weighed in on TNXP. Aegis started coverage on Tonix Pharmaceuticals Holding Corp. in a report on Monday, June 26th. They issued a “buy” rating and a $10.00 target price on the stock. Dawson James reissued a “buy” rating and issued a $9.00 target price on shares of Tonix Pharmaceuticals Holding Corp. in a research report on Wednesday, August 23rd. Drexel Hamilton initiated coverage on Tonix Pharmaceuticals Holding Corp. in a research note on Tuesday, August 22nd. They set a “buy” rating for the company. Finally, Roth Capital upgraded Tonix Pharmaceuticals Holding Corp. from a “neutral” rating to a “buy” rating and set a $6.00 price target for the company in a research note on Friday, August 18th. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $8.33.

Tonix Pharmaceuticals Holding Corp. (NASDAQ TNXP) opened at 4.38 on Monday. The stock has a 50 day moving average of $3.90 and a 200 day moving average of $4.09. Tonix Pharmaceuticals Holding Corp. has a 1-year low of $0.33 and a 1-year high of $9.40. The stock’s market cap is $32.89 million.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) last released its quarterly earnings results on Monday, August 14th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.78) by $0.13. Equities analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post ($3.02) EPS for the current fiscal year.

WARNING: This story was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/10/04/valuengine-downgrades-tonix-pharmaceuticals-holding-corp-tnxp-to-strong-sell.html.

In other Tonix Pharmaceuticals Holding Corp. news, CEO Seth Lederman purchased 20,000 shares of the company’s stock in a transaction dated Thursday, August 17th. The shares were acquired at an average price of $3.00 per share, for a total transaction of $60,000.00. Following the purchase, the chief executive officer now directly owns 11,166 shares of the company’s stock, valued at approximately $33,498. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. 4.00% of the stock is currently owned by company insiders.

Several hedge funds have recently modified their holdings of the company. Citadel Advisors LLC purchased a new stake in shares of Tonix Pharmaceuticals Holding Corp. in the 1st quarter worth $119,000. Vanguard Group Inc. lifted its position in Tonix Pharmaceuticals Holding Corp. by 28.8% during the second quarter. Vanguard Group Inc. now owns 184,377 shares of the company’s stock valued at $799,000 after purchasing an additional 41,264 shares in the last quarter. Finally, B. Riley Financial Inc. purchased a new position in Tonix Pharmaceuticals Holding Corp. during the second quarter valued at $1,637,000. 28.27% of the stock is owned by hedge funds and other institutional investors.

About Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The company’s lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.

Analyst Recommendations for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

Receive News & Stock Ratings for Tonix Pharmaceuticals Holding Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals Holding Corp. and related stocks with our FREE daily email newsletter.